Fulcrum Therapeutics (FULC) Soars 14.31% on Earnings Report

Fulcrum Therapeutics (FULC) shares surged 0.76% today, marking the third consecutive day of gains, with a cumulative increase of 14.31% over the past three days. The stock price reached its highest level since September 2024, with an intraday gain of 4.20%.

Fulcrum Therapeutics recently released its Q2 2025 earnings report on July 30, 2025. This report is crucial as it provides investors with a comprehensive view of the company's financial performance and future outlook, which can significantly influence stock prices.

Additionally, there has been notable options trading activity involving Fulcrum Therapeutics within the Russell 3000 index. Unusual options activity often signals investor speculation about potential future movements in the stock price, adding to the volatility and interest in the company's shares.

In June, Fulcrum Therapeutics saw an increase in short interest, with 5,820,000 shares being shorted as of June 15th. This rise in short interest suggests that some investors anticipate a decline in the stock price, which can create additional pressure on the shares.